新规则已出!医生发SCI论文难度提升!

2018-04-11 三个鲁班 三个鲁班

近几天来,大家都在疯传ICMJE的新规则:Data Sharing Statements for Clinical Trials — A Requirement of the International Committee of Medical Journal Editors。 我们主要从三个方面来讨论。最后讨论ICMJE的最新规则。 1、动物伦理和临床试验的伦理:课题设计完成,在

近几天来,大家都在疯传ICMJE的新规则:Data Sharing Statements for Clinical Trials — A Requirement of the International Committee of Medical Journal Editors。

我们主要从三个方面来讨论。最后讨论ICMJE的最新规则。

1、动物伦理和临床试验的伦理:课题设计完成,在开始实验/试验之前,一定要拿到动物伦理和临床试验的伦理。伦理问题,尤其是临床试验的伦理,是比较重要的,一定要有。当然,目前关于动物伦理,也已有SCI期刊要求提供。

请看我们投稿后,编辑部在2017年的回复邮件中提出的意见,是不是很“惊喜”:

Title: ***

Dear Professor ***,

Please provide the name of the committee from which you received ethical approval for the use of rats in your study, and provide evidence of this approval. 

。。。

Yours sincerely, 

***

2、临床试验注册:课题设计完成后,临床试验的课题,对于“临床试验注册”,大家也一定要注意,没有注册,估计后续会没有机会投稿。这个问题,似乎大家重视程度不够。

大家先请看要求提供临床试验注册的邮件(邮件是2015年编辑部回复的):

Dear Dr. **:

Before proceeding with the review orioles can you confirm the clinical trial registry number?(编辑部要求我们提供临床试验注册的注册号).  I look forward to hearing from you.

Sincerely,

Dr. **

Journal of ***

大家再来看看编辑部因为作者没有按照ICMJE规则要求来注册,没有提前注册而是后补注册的后果(这个来自2016年编辑部的邮件):

Dear Dr. **,

Many thanks for clarifying the status of your clinical trial registration. Unfortunately, I cannot consider your manuscript further. As a journal, we adhere to the ICMJE guidelines, which require prospective trial registration(ICMJE的要求,前瞻性研究的临床试验,必须在纳入第一例病人前完成临床试验注册). In spite of the present decision, we look forward to submissions from you in the future.

Thank you for submitting your manuscript to the Journal of ***.

Yours sincerely

Dr. ***

然而,到这里,大家是不是认为:在还没有开始临床试验前,仅仅注册就可以了呢?看看下面最新的要求吧,目前的要求是越来越高!

3、ICMJE的新规:临床试验注册的数据,必须全部公开!!!这是最新的要求,就在6月初公布的。大家请看:

什么?什么?要全部公开?这是怎么回事??新规则下,医生还能不能好好发SCI论文了?

首先,我们看看ICMJE的要求是哪些?下图是ICMJE要求中提供的最新内容:

Therefore, ICMJE will require the following as conditions of consideration for publication of a clinical trial report in our member journals:

1. As of July 1, 2018, manuscripts submitted to ICMJE journals that report the results of clinical trials must contain a data sharing statement as described below.

2. Clinical trials that begin enrolling participants on or after January 1, 2019, must include a data sharing plan in the trial’s registration. The ICMJE’s policy regarding trial registration is explained at http://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration.html. If the data sharing plan changes after registration this should be reflected in the statement submitted and published with the manuscript and updated in the registry record.

简单翻译一下,就是:

第一,2018年7月及以后提交到ICMJE期刊的临床试验报告,必须包含数据共享声明。

第二,2019年1月1日后开始入组受试者的临床试验,必须在临床试验注册平台上提交数据共享计划。

ICMJE为何这么牛气?我们来看看ICMJE的情况,ICMJE是International Committee of Medical Journal Editors(国际医学期刊编辑委员会)的简称。

ICMJE的成员包括哪些期刊呢?医学领域的话,我们搜索了一下ICMJE的网站(http://www.icmje.org/),得到如下信息:

像什么NEJM、JAMA、Lancet、BMJ、Plos等都是ICMJE的成员。这个新的声明,估计后面会有全文的翻译版,目前在各大医学期刊上全文基本上都是免费下载的,大家可以自行前往查阅:

http://www.nejm.org/doi/full/10.1056/NEJMe1705439;

http://jamanetwork.com/journals/jama/fullarticle/2630773;

http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)31282-5/fulltext;

综上所述,后续大家在设计医学方面课题时,尤其是在实施前,各个规则都要考虑。不然,会给后面的发表带来不可控制的损失。新规则下,医生要想好好发SCI论文,就得遵守ICMJE的规则。

在投稿过程,编辑部返回的意见中,有的期刊在拒稿信中会写明需要遵守ICMJE和临床试验注册;而有的期刊只用一句话:不符合我们期刊刊文要求!草草打发掉,根本就不告诉我们到底是哪儿不符合,甚至发邮件咨询,编辑部还会说详情在for authors中。。。您老倒是告诉我们哪儿不行啊??

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1404498, encodeId=7da71404498fe, content=<a href='/topic/show?id=10aa1603137' target=_blank style='color:#2F92EE;'>#SCI论文#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16031, encryptionId=10aa1603137, topicName=SCI论文)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9c572475119, createdName=般若傻瓜, createdTime=Fri Apr 13 04:52:00 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574353, encodeId=702c15e43531b, content=<a href='/topic/show?id=3c2c586e23f' target=_blank style='color:#2F92EE;'>#新规#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58672, encryptionId=3c2c586e23f, topicName=新规)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2ca16016783, createdName=xsm923, createdTime=Fri Apr 13 04:52:00 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=304863, encodeId=cca43048638a, content=谢谢分享学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM7GibvIBibibnnnvpajk2stlDF5oichYahI6Bia8uxeTBFoPbdoHWebyXf9eal9FNgUF2lNcrwoZicM3BvQ/0, createdBy=a3742066385, createdName=戒馋,懒,贪, createdTime=Wed Apr 11 20:21:20 CST 2018, time=2018-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=304862, encodeId=7c9e304862bd, content=谢谢分享学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM7GibvIBibibnnnvpajk2stlDF5oichYahI6Bia8uxeTBFoPbdoHWebyXf9eal9FNgUF2lNcrwoZicM3BvQ/0, createdBy=a3742066385, createdName=戒馋,懒,贪, createdTime=Wed Apr 11 20:21:07 CST 2018, time=2018-04-11, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1404498, encodeId=7da71404498fe, content=<a href='/topic/show?id=10aa1603137' target=_blank style='color:#2F92EE;'>#SCI论文#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16031, encryptionId=10aa1603137, topicName=SCI论文)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9c572475119, createdName=般若傻瓜, createdTime=Fri Apr 13 04:52:00 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574353, encodeId=702c15e43531b, content=<a href='/topic/show?id=3c2c586e23f' target=_blank style='color:#2F92EE;'>#新规#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58672, encryptionId=3c2c586e23f, topicName=新规)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2ca16016783, createdName=xsm923, createdTime=Fri Apr 13 04:52:00 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=304863, encodeId=cca43048638a, content=谢谢分享学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM7GibvIBibibnnnvpajk2stlDF5oichYahI6Bia8uxeTBFoPbdoHWebyXf9eal9FNgUF2lNcrwoZicM3BvQ/0, createdBy=a3742066385, createdName=戒馋,懒,贪, createdTime=Wed Apr 11 20:21:20 CST 2018, time=2018-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=304862, encodeId=7c9e304862bd, content=谢谢分享学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM7GibvIBibibnnnvpajk2stlDF5oichYahI6Bia8uxeTBFoPbdoHWebyXf9eal9FNgUF2lNcrwoZicM3BvQ/0, createdBy=a3742066385, createdName=戒馋,懒,贪, createdTime=Wed Apr 11 20:21:07 CST 2018, time=2018-04-11, status=1, ipAttribution=)]
    2018-04-13 xsm923
  3. [GetPortalCommentsPageByObjectIdResponse(id=1404498, encodeId=7da71404498fe, content=<a href='/topic/show?id=10aa1603137' target=_blank style='color:#2F92EE;'>#SCI论文#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16031, encryptionId=10aa1603137, topicName=SCI论文)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9c572475119, createdName=般若傻瓜, createdTime=Fri Apr 13 04:52:00 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574353, encodeId=702c15e43531b, content=<a href='/topic/show?id=3c2c586e23f' target=_blank style='color:#2F92EE;'>#新规#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58672, encryptionId=3c2c586e23f, topicName=新规)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2ca16016783, createdName=xsm923, createdTime=Fri Apr 13 04:52:00 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=304863, encodeId=cca43048638a, content=谢谢分享学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM7GibvIBibibnnnvpajk2stlDF5oichYahI6Bia8uxeTBFoPbdoHWebyXf9eal9FNgUF2lNcrwoZicM3BvQ/0, createdBy=a3742066385, createdName=戒馋,懒,贪, createdTime=Wed Apr 11 20:21:20 CST 2018, time=2018-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=304862, encodeId=7c9e304862bd, content=谢谢分享学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM7GibvIBibibnnnvpajk2stlDF5oichYahI6Bia8uxeTBFoPbdoHWebyXf9eal9FNgUF2lNcrwoZicM3BvQ/0, createdBy=a3742066385, createdName=戒馋,懒,贪, createdTime=Wed Apr 11 20:21:07 CST 2018, time=2018-04-11, status=1, ipAttribution=)]
    2018-04-11 戒馋,懒,贪

    谢谢分享学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1404498, encodeId=7da71404498fe, content=<a href='/topic/show?id=10aa1603137' target=_blank style='color:#2F92EE;'>#SCI论文#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16031, encryptionId=10aa1603137, topicName=SCI论文)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9c572475119, createdName=般若傻瓜, createdTime=Fri Apr 13 04:52:00 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574353, encodeId=702c15e43531b, content=<a href='/topic/show?id=3c2c586e23f' target=_blank style='color:#2F92EE;'>#新规#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58672, encryptionId=3c2c586e23f, topicName=新规)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2ca16016783, createdName=xsm923, createdTime=Fri Apr 13 04:52:00 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=304863, encodeId=cca43048638a, content=谢谢分享学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM7GibvIBibibnnnvpajk2stlDF5oichYahI6Bia8uxeTBFoPbdoHWebyXf9eal9FNgUF2lNcrwoZicM3BvQ/0, createdBy=a3742066385, createdName=戒馋,懒,贪, createdTime=Wed Apr 11 20:21:20 CST 2018, time=2018-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=304862, encodeId=7c9e304862bd, content=谢谢分享学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM7GibvIBibibnnnvpajk2stlDF5oichYahI6Bia8uxeTBFoPbdoHWebyXf9eal9FNgUF2lNcrwoZicM3BvQ/0, createdBy=a3742066385, createdName=戒馋,懒,贪, createdTime=Wed Apr 11 20:21:07 CST 2018, time=2018-04-11, status=1, ipAttribution=)]
    2018-04-11 戒馋,懒,贪

    谢谢分享学习了

    0

相关资讯

SCI论文的那些事@投稿的流程(上)

1、SCI论文是什么? SCI论文是说你的论文被检索机构SCI收录,SCI的全称是Science Citation Index科学引文索引。我们投稿时候需要关心的不是我们的论文会不会被检索,而是看投稿的杂志是不是被科学引文索引数据库所收录。 SCI论文,即为被SCI索引收录的期刊所刊登的论文,目前我国科技界对SCI论文概念模式,小部分研究者误认为SCI是一本期刊,而由于南京大学率先引用

医学SCI论文的结构化写作(转载)

一篇优秀的SCI论文一般由规范而严谨的内容和适当的论文结构和语言表达构成。内容是文章的灵魂,语言结构是论文的骨架。本文系统的讲述医学SCI论文的结构化写作,希望对各位有所启发。

没收到元宵福利的,到这儿来拿吧!

法轮天上转,梵声天上来; 灯树千光照,花焰七枝开。 月影疑流水,春风含夜梅; 燔动黄金地,钟发琉璃台。 昨夜花好月圆,外面游人如织,好不热闹,猜灯谜,赏花灯,还有“月上柳梢头,人约黄昏后”朦胧。明明外面的风景是让你无限向往的,明明内心最大声的咆哮是我要和家人过元宵!但是你的眼睛却无法离开显示屏,满屏的数据和表格,内心的焦虑早已把你吞没

林墨:新中国第一篇SCI论文

本文由于数据问题,暂时撤稿,更多资讯请关注Medsci.cn!

学术论文写作的九阶段

Q:「该如何将写作过程分成不同步骤,让我可以依循这些步骤完成文章?」——清华大学,博士班学生A:多数的作者在进行论文写作时,鲜少注意到写作正进行到哪个阶段,因而常感到不知所措。我们可以将写作流程细分为九个阶段,并遵循着每个步骤,从而掌握写作进度及要领,顺利写出一篇优秀的学术论文。1. 思考论文雏形在正式开始之前,花5到10分钟来沉淀心灵吧!写下任何盘旋在您脑海中的事情,无论是需要完成的差事或是

学术不端的十大类别

2014年,我们发表了《Wiley针对抄袭的举措》。对于每一篇使用ScholarOne系统提交到Wiley开放获取期刊的稿件,iThenticate反抄袭软件会自动生成一份报告,这一惠及编辑和作者双方的过程,可确保开放获取的流程具有更高的学术伦理规范。 然而抄袭仍然是学术出版业的一大问题。为了解决屡见不鲜的抄袭问题,我们需要更深刻地认识抄袭的本质。 根据这个思路,iThenti